CSIMarket Company Name, Ticker, Industry, else..
 
Larimar Therapeutics Inc   (NASDAQ: LRMR)
 

Larimar Therapeutics Inc's Suppliers Performance

LRMR's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
LRMR Costs vs Sales of Suppliers Growth

• More on LRMR Suppliers






Larimar Therapeutics Inc's Comment on Supply Chain


The company utilizes contract manufacturers and research organizations to develop manufacturing processes and analytical methods for drug substances and drug products in support of clinical trials, complying with current Good Manufacturing Practices (cGMP). Third-party manufacturers handle clinical packaging, storage, and distribution of nomlabofusp. The nomlabofusp master cell bank and working cell bank are stored at separate third-party locations. KBI Biopharma, Inc. manufactures the drug substance in frozen liquid form under a Master Services Agreement. A lyophilized drug product is produced from this drug substance by another supplier. Lonza has been selected to support scale-up efforts for global commercial demand, with technology transfer and process scale-up completed under a Master Services Agreement. Additional comparability studies of the drug substance manufactured by Lonza are required for regulatory approval. The company is optimizing manufacturing processes to increase yields, reduce costs, and improve supply chain reliability. Process performance qualification for commercial-scale manufacturing is nearing completion in preparation for Biologics License Application (BLA) submission and U.S. commercial launch.

Larimar Therapeutics Inc's Comment on Supply Chain


The company utilizes contract manufacturers and research organizations to develop manufacturing processes and analytical methods for drug substances and drug products in support of clinical trials, complying with current Good Manufacturing Practices (cGMP). Third-party manufacturers handle clinical packaging, storage, and distribution of nomlabofusp. The nomlabofusp master cell bank and working cell bank are stored at separate third-party locations. KBI Biopharma, Inc. manufactures the drug substance in frozen liquid form under a Master Services Agreement. A lyophilized drug product is produced from this drug substance by another supplier. Lonza has been selected to support scale-up efforts for global commercial demand, with technology transfer and process scale-up completed under a Master Services Agreement. Additional comparability studies of the drug substance manufactured by Lonza are required for regulatory approval. The company is optimizing manufacturing processes to increase yields, reduce costs, and improve supply chain reliability. Process performance qualification for commercial-scale manufacturing is nearing completion in preparation for Biologics License Application (BLA) submission and U.S. commercial launch.







LRMR's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Larimar Therapeutics Inc 0.00 0.00 -172.61 71
SUBTOTAL 0.00 0.00 0.00 -


Sources: Larimar Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Larimar Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.